Verona Pharma PLC
NASDAQ:VRNA
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
11.48
45.28
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Verona Pharma PLC
Wall Street
Price Targets
VRNA Price Targets Summary
Verona Pharma PLC
According to Wall Street analysts, the average 1-year price target for
VRNA
is 47.94 USD
with a low forecast of 36.36 USD and a high forecast of 67.2 USD.
VRNA Last Price Targets
Verona Pharma PLC
The latest public price target was made on Nov 5, 2024 by
Raghuram Selvaraju
from
H.C. Wainwright
,
who expects
VRNA
stock to
drop by 7%
over the next 12 months.
You can read more about this price target by viewing
the article on StreetInsider.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
|
Raghuram Selvaraju
H.C. Wainwright
|
42
USD
Downside 7% |
1 month ago
Nov 5, 2024
|
Verona Pharma (VRNA) PT Raised to $42 at H.C. Wainwright
StreetInsider
|
Edward Nash
Canaccord Genuity
|
37
USD
Downside 18% |
5 months ago
Jul 22, 2024
|
Verona Pharma (VRNA) PT Raised to $37 at Canaccord Genuity
StreetInsider
|
|
Raghuram Selvaraju
H.C. Wainwright
|
36
USD
Downside 20% |
5 months ago
Jun 27, 2024
|
Verona Pharma price target raised to $36 from $32 at H.C. Wainwright
TheFly
|
Andrew Tsai
Jefferies
|
38
USD
Downside 16% |
6 months ago
May 28, 2024
|
Expert likely to prescribe more ensifentrine than dupixent, says Jefferies
TheFly
|
Yasmeen Rahimi
Piper Sandler
|
36
USD
Downside 20% |
8 months ago
Apr 16, 2024
|
Verona Pharma (VRNA) PT Raised to $36 at Piper Sandler
StreetInsider
|
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is VRNA's stock price target?
Price Target
47.94
USD
According to Wall Street analysts, the average 1-year price target for
VRNA
is 47.94 USD
with a low forecast of 36.36 USD and a high forecast of 67.2 USD.
You don't have any saved screeners yet
